ArticleFrontiers in endocrinology2026
Establishment of the endocrine variant extractor and its clinical application in identifying a novel
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genetic diagnosis of endocrine disorders is often hampered by the complexity of analyzing Whole Exome Sequencing (WES) data. We developed the endocrine variant extractor (EVE), a streamlined, clinician-friendly bioinformatics pipeline designed for multi-tier genetic screening with a core panel for parathyroid disorders (26 genes) and an expanded endocrine panel for broader metabolic assessment (413 genes, fully encompassing the parathyroid panel). Methods: Encapsulated within a Docker container and automated via a custom Python wrapper, EVE integrates core bioinformatics engines, including BWA-MEM, GATK, and SnpEff. The pipeline employs a tiered reporting strategy, filtering and annotating variants across both panels using pathogenicity scores (SIFT, PolyPhen-2) and clinical databases (ClinVar, gnomAD). This architecture ensures cross-platform compatibility without complex manual configuration. Results: To validate the pipeline, EVE was applied to clinical datasets. EVE successfully filtered >300,000 raw variants down to a handful of actionable candidates. Using this pipeline, we precisely identified the first Korean case of a Conclusion: EVE provides a streamlined, high-efficiency workflow that automates the filtering of thousands of raw WES variants into a curated list of clinically relevant variants. This robust framework enables the creation of a comprehensive "endocrine variant atlas," empowering clinicians to integrate high-throughput genetic profiling into routine diagnostics and accelerate the discovery of novel disease-causing variants. The complete source code for EVE is freely available at https://github.com/hanyunseo01/EVE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.